Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Coronavirus disease 2019 (COVID-19) was first diagnosed in Scotland on 1 March 2020. During the first month of the outbreak, 2,641 cases of COVID-19 led to 1,832 hospital admissions, 207 intensive care admissions and 126 deaths. We aimed to identify the source and number of introductions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into Scotland using a combined phylogenetic and epidemiological approach. Sequencing of 1,314 SARS-CoV-2 viral genomes from available patient samples enabled us to estimate that SARS-CoV-2 was introduced to Scotland on at least 283 occasions during February and March 2020. Epidemiological analysis confirmed that early introductions of SARS-CoV-2 originated from mainland Europe (the majority from Italy and Spain). We identified subsequent early outbreaks in the community, within healthcare facilities and at an international conference. Community transmission occurred after 2 March, 3 weeks before control measures were introduced. Earlier travel restrictions or quarantine measures, both locally and internationally, would have reduced the number of COVID-19 cases in Scotland. The risk of multiple reintroduction events in future waves of infection remains high in the absence of population immunity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41564-020-00838-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of alternative clinical samples for the detection of SARS-CoV-2 and influenza virus by automated multiplex RT-PCR.
J Infect Dev Ctries
August 2025
Department of Medical Microbiology, Faculty of Medicine, Ege University, Izmir 35100, Turkey.
Introduction: The aim of this study was to compare the performance of different clinical specimens-nasopharyngeal (NP) swabs collected by healthcare professionals (HCP-NP), self-collected nasal swabs (Sc-N), and saliva samples (S)-in diagnostic tests for investigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and influenza A/B RNA.
Methodology: These clinical samples were collected from 404 symptomatic cases and tested with the SARS-CoV-2 and influenza A/B RNA tests on the cobas 6800 System of Roche Molecular Systems (Roche Molecular Systems, Pleasanton, USA). The SARS-CoV-2 or influenza virus infection status was determined for all patients based on the predefined criteria and corresponding algorithms.
Post COVID attitude, intent, awareness and preparedness of public to combat monkeypox infection in Odisha state, India.
J Infect Dev Ctries
August 2025
Department of Oral Radiology, College of Dentistry, Jouf University, Kingdom of Saudi Arabia.
Introduction: The coronavirus disease 2019 (COVID-19) pandemic highlighted the importance of public knowledge, vaccination, government preparedness, and a strong healthcare system in managing infectious diseases. Recently, monkeypox (mpox) cases have emerged globally. This study aimed to assess: (i) the public knowledge related to COVID-19 and its translation into preventive behavior, and (ii) the preparedness of the government and healthcare providers in addressing mpox.
View Article and Find Full Text PDFAge and sex distribution trends of SARS-CoV-2 infections: Insights from three epidemic waves in Puducherry, India.
J Infect Dev Ctries
August 2025
ICMR-Vector Control Research Centre, Puducherry, India.
Introduction: This study analyzed the age and sex distribution of COVID-19 patients during the initial three COVID-19 waves in Puducherry, India, from August 2020 to March 2022, to understand the distribution of infection across different demographic groups.
Methods: The disease surveillance program conducted at ICMR-Vector Control Research Centre processed 79,705 Throat Swab/Nasal Swab (TSNS) samples received from various institutions in Puducherry through the Integrated Disease Surveillance Program (IDSP). Real-time reverse-transcriptase-polymerase chain reaction (rRT-PCR) was performed following approved protocols.
Propofol emulsification in Intralipid and SMOFlipid: A promising alternative in response to future shortages.
PLoS One
September 2025
Plateforme de Biopharmacie, Université de Montréal, Montréal, Quebec, Canada.
Introduction: The Covid-19 pandemic has intensified shortages in various pharmaceutical products, notably injectable propofol in lipid emulsion form. Its demand surged sharply due to its critical role in intubating patients with respiratory distress during the pandemic, exposing vulnerabilities in the supply chain for this essential product.
Objectives: This project aims to develop an alternative formulation to commercially available propofol products and to evaluate its stability through a detailed study.
Breakthrough SARS-CoV-2 outcomes in immune-disordered people during the Omicron era: a prospective cohort study.
BMJ Public Health
August 2025
Epidemiology and Data Management Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases Division of Intramural Research, Bethesda, Maryland, USA.
Introduction: Immune-deficient/disordered people (IDP) elicit a less robust immune response to COVID-19 vaccination than the general US population. Despite millions of IDP at presumed elevated risk, few population-level studies of IDP have been conducted in the Omicron era to evaluate breakthrough infection-related outcomes.
Methods: We followed a prospective cohort of 219 IDP and 63 healthy volunteers (HV) in the USA from April 2021 (Alpha variant peak) to July 2023 (Omicron XBB variant peak).